Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC

  • Yoshiaki AminoEmail author
  • Satoru Kitazono
  • Shinya Uematsu
  • Tsukasa Hasegawa
  • Takahiro Yoshizawa
  • Ken Uchibori
  • Noriko Yanagitani
  • Atsushi Horiike
  • Takeshi Horai
  • Kazuo Kasahara
  • Makoto Nishio
Original Article



Chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Recently, anti-PD-1 antibody therapy became a key treatment for stage IV NSCLC as the combination of immune checkpoint inhibitors (ICIs) and platinum doublet chemotherapy. However, the efficacy and toxicity of anti-PD-1 therapy for recurrence after CRT in stage III NSCLC are not well examined.


Patients who received anti-PD-1 therapy for recurrence after CRT were identified in our clinical database. The safety and efficacy of anti-PD-1 therapy were retrospectively analyzed.


From March 1, 2013 to April 30, 2018, there were 20 patients who received anti-PD-1 therapy for recurrence after CRT. The median duration from CRT to initial anti-PD-1 therapy was 9.3 months. 12 patients (60%) were alive and 7 patients (35%) were still receiving anti-PD-1 therapy at the data cutoff point (median follow-up, 13.5 months). The ORR for anti-PD-1 therapy was 45.0%. Median progression-free survival (PFS) and overall survival (OS) from initiation of anti-PD-1 therapy was 8.4 months and 26.2 months, respectively. PFS in patients who had a short interval from last CRT to initial anti-PD-1 therapy seemed to have better outcomes (duration from last CRT to initial anti-PD-1 therapy < 9.3 months vs. ≥ 9.3 months; median PFS, 17.0 months vs. 4.9 months). Grade 3 or 4 immune-related adverse events occurred in 5% of patients. Only grade 1 pneumonitis was observed.


The efficacy of anti-PD-1 therapy for recurrence after CRT in stage III NSCLC might better than in stage IV NSCLC. The duration from CRT to initial anti-PD-1 therapy might be related to efficacy.


Non-small cell lung cancer Chemoradiotherapy Anti-PD-1 therapy 


Compliance with ethical standards

Conflict of interest

All the authors approved the submission this manuscript to your journal. Makoto Nishio reports honoraria from Ono, BMS, Pfizer, Chugai,Taiho Pharmac, AstraZeneca, Boehringer-ingelheim, MSD, and Novartis, research funding from Novartis, Daiichi Sankyo, Taiho Pharma, BMS, Boehringer-ingelheim, Ono Phrmaceutical, Eli Lilly, Chugai, AstraZeneca, Merck Sernon, MSD and Pfizer. Noriko Yanagitani reports employment/ledership position/ advisory role of Chugai Phrmaceutical. Atsushi Horiike reports horaria from chugai pharma, AstraZeneca, Pfizer, Ono Phrmaceutical, Bristol-Myers Squibb Japan, A2 Healthcare and MSD oncology, research funding from Chugai Pharma, MSD Oncology, Abbvie, AstraZeneca and Loxo. We agree to allow the journal to review our data if requested.


  1. 1.
    Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol 28(13):2181–2190CrossRefGoogle Scholar
  2. 2.
    Ryan KJ, Skinner KE, Fernandes AW et al (2019) Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Med Oncol 36(3):24CrossRefGoogle Scholar
  3. 3.
    Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8(1):1–20CrossRefGoogle Scholar
  4. 4.
    McCall NS, Dicker AP, Lu B (2018) Beyond concurrent chemoradiation: the emerging role of PD-1/PD-L1 inhibitors in stage III lung cancer. Clin Cancer Res 24(6):1271–1276CrossRefGoogle Scholar
  5. 5.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378(22):2078–2092CrossRefGoogle Scholar
  6. 6.
    Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 379(21):2040–2051CrossRefGoogle Scholar
  7. 7.
    Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301CrossRefGoogle Scholar
  8. 8.
    Jotte RM, Cappuzzo F, Vynnychenko I et al (2018) IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 36(18_suppl):LAB9000CrossRefGoogle Scholar
  9. 9.
    West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(7):924–937CrossRefGoogle Scholar
  10. 10.
    Herbst RS, Baas P, Kim D-W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550CrossRefGoogle Scholar
  11. 11.
    Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefGoogle Scholar
  12. 12.
    Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135CrossRefGoogle Scholar
  13. 13.
    Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265CrossRefGoogle Scholar
  14. 14.
    Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929CrossRefGoogle Scholar
  15. 15.
    Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350CrossRefGoogle Scholar
  16. 16.
    Takano N, Ariyasu R, Koyama J et al (2019) Improvement in the survival of patients with stage IV non-small-cell lung cancer: experience in a single institutional 1995–2017. Lung Cancer 131:69–77CrossRefGoogle Scholar
  17. 17.
    Demaria S, Ng B, Devitt ML et al (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58(3):862–870CrossRefGoogle Scholar
  18. 18.
    Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig 124(2):687–695CrossRefGoogle Scholar
  19. 19.
    Dovedi SJ, Adlard AL, Lipowska-Bhalla G et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Can Res 74(19):5458CrossRefGoogle Scholar
  20. 20.
    Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325–1332CrossRefGoogle Scholar
  21. 21.
    Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903CrossRefGoogle Scholar
  22. 22.
    Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373CrossRefGoogle Scholar
  23. 23.
    McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463–1469CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Yoshiaki Amino
    • 1
    Email author
  • Satoru Kitazono
    • 1
  • Shinya Uematsu
    • 1
  • Tsukasa Hasegawa
    • 1
  • Takahiro Yoshizawa
    • 1
  • Ken Uchibori
    • 1
  • Noriko Yanagitani
    • 1
  • Atsushi Horiike
    • 1
  • Takeshi Horai
    • 1
  • Kazuo Kasahara
    • 2
  • Makoto Nishio
    • 1
  1. 1.Department of Thoracic Medical OncologyCancer Institute Hospital of Japanese Foundation for Cancer ResearchKotoJapan
  2. 2.Hematology/Respiratory Medicine, Kanazawa University Faculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawaJapan

Personalised recommendations